

Latent Class Analysis of COVID-19 Deaths by Comorbidities— United States, February-May 2020

David A. Siegel, MD, MPH^a, William A. Bentley, MS^a, Rongxia Li, PhD^a, Carolyn V. Gould, MD, MSCR^a, David W. McCormick, MD, MPH^a, Joseph McLaughlin, MD, MPH,^b Anjali Vyas, MBBS., MS, MPH^c, Charles R. Clark, MPH^d, Gillian Richardson, MPH^e, Anna Krueger, MS^f, Stacy Holzbauer, DVM, MPH^g, Leslie Kollmann CVT^g, Deepam Thomas, MPH^h, Mojisola Ojo, MPH^h, Marc Paladini, MPHⁱ, Kathleen H. Reilly, PhD, MPHⁱ, Meagan McLafferty, MPH^j, Dean E. Sidelinger, MD, MSED^j, Laura C. Chambers, PhD, MPH^k, Jennifer S. Read, MD, MS, MPH^l, Mona Saraiya, MD^a, Paul R Young, MD^a, Jonathan M. Wortham, MD^a, Emilia H. Koumans, MD, MPH^a

Affiliations:

^aCDC COVID-19 Emergency Response Team, Centers for Disease Control and Prevention, 4770 Buford Hwy NE, MS-76, Atlanta, GA 30341, USA

^bAlaska Department of Health and Social Services, 3601 C St #902, Anchorage, AK 99503, USA

^cHawaii State Department of Health, 1250 Punchbowl St, Honolulu, HI 96813, USA

^dIndiana Department of Health, 2 N Meridian St, Indianapolis, IN 46204, USA

^eLouisiana Department of Health, 628 N 4th St, Baton Rouge, LA 70802, USA

^fMaine Center for Disease Control and Prevention, State House Station 11, 286 Water St, Augusta, ME 04333, USA

^gMinnesota Department of Health, P.O. Box 64975, St. Paul, MN 55164-0975, USA

^hNew Jersey Department of Health, P.O. Box 360, Trenton, NJ, USA

ⁱNew York City Department of Health and Mental Hygiene, 42-09 28th St; Long Island City, NY 11101, USA

^jOregon Health Authority, 800 NE Oregon St, Portland, OR 97232, USA

^kRhode Island Department of Health, 3 Capitol Hill, Providence, RI 02908, USA

^lInfectious Disease Epidemiology, Vermont Department of Health, 108 Cherry Street, Burlington, VT 05402, USA; Larner College of Medicine, University of Vermont, Given Medical Bldg, E-126, 89 Beaumont Ave, Burlington, VT 05405, USA

Corresponding Author:

David A Siegel, MD, MPH
4770 Buford Hwy NE, MS-76
Atlanta, GA 30341
Phone: 770-488-4426
Email: irm3@cdc.gov

CRedit roles:

David A. Siegel: Original draft preparation, Visualization, Conceptualization, Methodology, Writing- Reviewing and Editing

Mona Saraiya: Conceptualization, Methodology, Writing- Reviewing and Editing

Emily Koumans, Carolyn V. Gould: Supervision, Conceptualization, Visualization, Methodology, Writing-Reviewing and Editing

William Bentley, Rongxia Li: Methodology, Visualization, Formal Analysis, Writing- Reviewing and Editing

David McCormick: Methodology, Visualization, Writing- Reviewing and Editing
Paul Rashad Young, Jonathan Wortham: Methodology, Writing- Reviewing and Editing
All other authors (Joseph McLaughlin, Anjali Vyas, Charles R. Clark, Gillian Richardson, Anna Krueger, Stacy Holzbauer, Leslie Kollmann. Deepam Thomas, Mojisola Ojo, Marc Paladini, Kathleen H. Reilly, Meagan McLafferty, Dean E. Sidelinger, Laura C. Chambers, Jennifer S. Read): Data curation, Visualization, Writing-reviewing and editing

No conflicts of interests are noted.

Disclaimer: The conclusions, findings, and opinions expressed by the authors do not necessarily reflect the official position of the Centers for Disease Control and Prevention or the authors' affiliated institutions.

Latent Class Analysis of COVID-19 Deaths by Comorbidities— United States, February-May 2020

Abstract:

Purpose: Risk factors for coronavirus disease 2019 (COVID-19) mortality include older age, cardiovascular disease, diabetes, and other comorbidities. Latent class analysis (LCA) can identify unrecognized morbidity patterns for decedents with COVID-19.

Methods: Data were collected from 23 U.S. jurisdictions about decedents with COVID-19 early in the COVID-19 pandemic (February 12–May 12, 2020). LCA identified groups of individuals based upon pre-existing comorbidities: cardiovascular, renal, lung, neurologic, and liver disease; obesity; diabetes; and immunocompromised state. Results were stratified by sex, age, race/ethnicity, and location of death.

Results: Of 12,340 decedents, LCA identified three classes, which included classes with prominent cardiovascular disease and diabetes (32%), prominent cardiovascular disease without diabetes (19%), and a “minimal prevalence” class (49%) with a low frequency of comorbidities. Individuals in the “minimal prevalence” class had risk factors in <2 comorbidity groups, where cardiovascular disease was the most common for individuals with a single comorbidity.

Conclusions: LCA analysis reaffirms the importance of diabetes and cardiovascular disease as risk factors for COVID-19 mortality and indicates that about half of decedents were in the “minimal prevalence” group. Results could guide vaccination and treatment messaging to groups with no or few underlying conditions.

Key Words: COVID-19, Mortality, Latent Class Analysis

Abbreviations:

Centers for Disease Control and Prevention (CDC)

Coronavirus disease 2019 (COVID-19)

Human immunodeficiency virus (HIV)

Latent class analysis (LCA)

Polymerase chain reaction (PCR)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Introduction

Numerous risk factors have been independently associated with increased risk of coronavirus disease 2019 (COVID-19)-related mortality; regression analyses have identified male sex,^{1, 2} older age,²⁻⁹ obesity,^{6, 10} cardiovascular disease,^{4, 11} diabetes,^{8, 12} and other comorbidities as being associated with death.^{4, 13} Despite these previous studies of risk factors for COVID-19-related mortality, unrecognized subgroups of individuals and their demographic and clinical characteristics may exist that could inform public health interventions, such as vaccination and direction of treatment, to prevent future deaths.

Latent class analysis (LCA) is a well-validated modeling technique that classifies individuals into subgroups based upon unobservable, unbiased patterns of disease manifestation and has not been widely utilized to describe patient characteristics with COVID-19.^{14, 15} The objective of this study is to use LCA to assess previously unobserved differences among decedents with COVID-19 and whether those groupings are associated with certain demographic characteristics.

Materials and methods

The Centers for Disease Control and Prevention (CDC) solicited information on individuals who died with COVID-19 from state, territorial, and local public health departments.¹⁶ Among 56 public health departments contacted by CDC, 23 provided data as part of this request. Individuals were included if they died during February 12–May 12, 2020 and had been diagnosed with PCR-positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Case data were abstracted from medical charts and death certificates by participating public health departments. Available demographic data included sex, age, race/ethnicity, and location of death (e.g., home, hospital). Comorbidities were categorized based upon recognized risk factors for mortality^{4, 8, 16-18} and included cardiovascular disease, diabetes, renal disease, chronic lung disease, immunocompromised state, neurologic disease, obesity, and liver disease. Specifically, comorbidities included cardiovascular disease (congenital heart disease, coronary artery disease, congestive heart failure, hypertension, cerebrovascular accident/stroke, valvular heart disease, conduction disorders or dysrhythmias, pulmonary hypertension, dyslipidemia, thrombosis, other cardiovascular disease), diabetes mellitus types I and II, chronic kidney disease (chronic kidney disease, end-stage renal disease, other kidney diseases), chronic lung disease (chronic obstructive pulmonary disease/emphysema, asthma, tuberculosis, other chronic lung diseases), immunocompromised state (cancer, human immunodeficiency virus [HIV] infection, lupus, ulcerative colitis, Crohn's disease, identified as being immunosuppressed), neurologic conditions (dementia, seizure disorder, other neurologic conditions), obesity (body mass index ≥ 30 kg/m²), and chronic liver disease (cirrhosis, alcoholic hepatitis, chronic liver disease, end-stage liver disease, hepatitis B, hepatitis C, nonalcoholic steatohepatitis, other chronic liver

diseases). A decedent with comorbidities in the same group (e.g., heart failure and stroke) was only counted in that comorbidity group (e.g., cardiovascular disease) once. Presence of a comorbidity was determined through medical chart review to be yes, no, or unknown (including missing). Other comorbidities outside of these eight groups were not uniformly reported by participating jurisdictions and were therefore not included in this analysis.

LCA modeling was used to identify characteristics that clustered among decedents using comorbidity groups.¹⁹ To select the appropriate number of classes, two-, three-, and four-class models were first fit to the data. A three-class model was selected based on the Bayesian information criterion. Thirty replications of the model were run with a maximum of 10,000 iterations each to maximize the chance of finding a good global fit and avoid local maximums. Individuals were assigned exclusively to one of the three classes according to their highest probability of membership.¹⁹ P-values were calculated from Pearson's chi-squared test to compare the distribution of variables. LCA was run for the entire study population and then separately for each age group. Classes were named after the 1 or 2 comorbidities with the highest prevalence or as "minimal prevalence" class where the prevalence of each comorbidity group was less than that of the entire sample. Data analysis was performed using R (version 4.0.3) and SAS (version 9.4, SAS Institute, Cary, NC); LCA was performed by the R package version 1.4.1.^{20, 21} This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.¹

¹ See e.g., 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.

Results

Among 12,340 decedents with COVID-19, 60% were male, 75% were age 65 years or older, 32% were non-Hispanic White, 24% were non-Hispanic Black, and 21% were Hispanic (Table 1). Of decedents, 60% were from New York City, 18% were from New Jersey, 8% were from Washington state, and 14% were from other public health departments. Two-thirds (66%) of decedents died in the hospital, 7% in long-term care facilities, 5% in emergency departments, and for 12% location of death was unknown. The most common comorbidities were cardiovascular disease (58%), followed by diabetes (36%), renal disease (20%), and chronic lung disease (18%).

LCA of all ages combined identified three classes of individuals (Table 1): a “diabetes and cardiovascular” class (n=3955, 32% of decedents), a “cardiovascular without diabetes” class (n=2387, 19%), and a “minimal prevalence” class (n=5998, 49%). In the “diabetes and cardiovascular” class, 100% of decedents had diabetes, 93% had cardiovascular disease, and 38% had renal disease. In the “cardiovascular without diabetes” class, 89% of decedents had cardiovascular disease, 39% had chronic lung disease, and 37% had neurologic disease. In the “minimal prevalence” class, which represented individuals with 0 or 1 comorbidity groups, 23% of decedents had cardiovascular disease, and all other conditions had a prevalence of $\leq 7\%$.

Across age groups, the ≥ 85 years age group had the highest proportion of decedents grouped into the “minimal prevalence” class (57%). The “diabetes and cardiovascular” class was more common among non-Hispanic Black (44%) than non-Hispanic White (22%) decedents, and the “minimal prevalence” class was most common among non-Hispanic White (54%) and non-Hispanic Asian decedents (51%), compared with non-Hispanic Black decedents (38%).

When LCA was run separately for each age group, each age group consisted of a class with cardiovascular disease being the most prevalent comorbidity group, a class where the most prevalent comorbidity varied, and a "minimal prevalence" class where the prevalence of each comorbidity group was less than that of the entire sample (Table 2).

Discussion

This study describes mortality patterns among individuals, mostly in the Northeast United States, early in the COVID-19 pandemic, and reflects patterns of death for individuals before antivirals or vaccination against SARS-CoV-2 was available. Nearly half of all decedents with COVID-19 could be subtyped into a class with a low frequency of measured comorbidities; this class represented individuals with 0 or 1 comorbidities, of which cardiovascular disease was the most common. Conversely, about half of decedents could be subtyped into a class with a predominant prevalence of cardiovascular disease or diabetes. Racial/ethnic differences were seen in the percentage of decedents in the "minimal prevalence" class, with non-Hispanic Whites having a higher proportion within this class among all non-Hispanic White decedents than the proportion of non-Hispanic Blacks who were within this class among all non-Hispanic Black decedents.

The presence of classes with a high prevalence of cardiovascular disease and diabetes indicates the importance of this morbidity pattern for individuals with COVID-19, consistent with prior literature.^{4, 22-24} Cardiovascular disease was present at 23% even in the "minimal prevalence" class, which might indicate the importance of this factor independent of other comorbidities. Other comorbidities such as renal, liver, and neurologic disease have been associated with higher COVID-19 mortality rates.⁸ Renal disease, which had a 20% prevalence

in this study population, was the third most prevalent comorbidity in the “diabetes/cardiovascular” class. Chronic lung disease was the second most prevalent condition in the “cardiovascular without diabetes” class. Past studies have found chronic pulmonary or respiratory disease to be a risk factor for mortality.^{11, 24}

Non-Hispanic Black and non-Hispanic White decedents had the lowest and highest percentages in the “minimal prevalence” class, respectively. Some studies have found that race is independently associated with a higher risk of death with COVID-19.^{8, 9, 11, 25, 26} Disparities among races and ethnicities in mortality with COVID-19 could be related to a number of factors such as prevalence of infection, presence of comorbidities, or societal factors.²⁷ However, when adjusting for clinical and sociodemographic factors, race might not be an independent predictor of mortality with COVID-19.²⁵

Older age is a well-established risk factor for mortality with COVID-19,⁴ which is reflected in the decedent age distribution of this study; 75% were age 65 years or older. Despite this age distribution, the presence of a “minimal prevalence” class with low frequencies of measured comorbidities persisted across all age groups, ranging from 57% of cases with ages ≥ 85 years to 38% of cases in the 55-64 years age group. The baseline prevalence of comorbidities by age in this report is consistent with other reports of age-specific baseline prevalence of comorbidities.^{28, 29} A large proportion (57%) of decedents aged 85 years or older were in the “minimal prevalence” class, which might be because age was their primary risk factor for death with COVID-19. Older decedents in this study might have had multiple comorbidities within the same group (e.g., stroke and heart failure), had more severe comorbidities, or had comorbidities not measured by this study (e.g., gastrointestinal, musculoskeletal, or psychiatric conditions).

This analysis has several limitations. First, this analysis represents a convenience sample of individuals who died with COVID-19 and represents approximately 15% of the 80,000 individuals who had died with COVID-19 nationwide by May 12, 2020.³⁰ Additionally, because most of decedents in this study were from New York City and New Jersey, these findings mostly represent a Northeast, urban population and might not be generalizable nationally. Second, there might have been variation in SARS-CoV-2 testing protocols among health departments and resulting variation in case ascertainment. Third, there might have been variation in diagnosis and recording of comorbidities; some comorbidities might be present but undiagnosed, and recording of comorbidities might vary by source of case ascertainment (e.g., death certificate). Fourth, only eight comorbidity groups were represented in these data. Other pre-existing comorbidities might have been present and were unmeasured, for example, disabilities, which have been linked to higher risk of severe disease with COVID-19.³¹ Fifth, socioeconomic status was not collected, limiting the ability of assessing access to care and its association with mortality. Sixth, the study did not quantify the number of people included in the study who had COVID-19 but died from an unrelated cause. Finally, these data represent disease early in the pandemic and reflect patterns of death before interventions such as dexamethasone were widespread, early in the course of nationwide prevention efforts (e.g., mask mandates), emergence of variants, and COVID-19 vaccination.

Individuals with older age, cardiovascular disease alone, or cardiovascular disease in combination with diabetes, represent distinct subpopulations that could be targets for COVID-19 prevention efforts, such as mitigation measures and vaccination promotion. Conversely, decedents in the “minimal prevalence” class across all age categories largely did not have diabetes and cardiovascular disease; this group represented a subpopulation with mortality risk

factors mostly independent from the eight comorbidities included in this report. However, cardiovascular disease was the most common single comorbidity. Communication directed to individuals in a potential “minimal prevalence” class could emphasize the importance of vaccination or antiviral therapy even for those without comorbidities such as diabetes and cardiovascular disease. Over two-thirds of individuals aged 18-25 years who were not planning on getting the COVID-19 vaccine cited it was because “I am not a member of a high-risk group.” Further evaluation of a potential “minimal prevalence” class could benefit messaging for individuals in this group.³² Alternatively, individuals in a potential “minimal prevalence” class could have undiagnosed risk factors for death with COVID-19; for these individuals, maintaining routine medical care could be helpful in identifying potential underlying conditions. Future research using latent class analysis could identify how additional factors may have contributed to severity and mortality clusters among individuals with COVID-19.

Acknowledgements: Sandy Althomsons, James Lee, Michigan Department of Health and Human Services, Lansing, MI, North Carolina Department of Health and Human Services, Raleigh, NC, Pennsylvania Department of Health, Harrisburg, PA, Wisconsin Department of Health Services, Madison, WI. We would additionally like to acknowledge staff from: California Department of Public Health, Colorado Department of Public Health and Environment, Connecticut Department of Public Health, Georgia Department of Public Health, Tennessee Department of Health, Utah Department of Health, Virginia Department of Health, and Washington State Department of Health.

References:

1. Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, et al. Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. *JAMA Netw Open*. 2020;3(6):e2012270. doi: 10.1001/jamanetworkopen.2020.12270.

2. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020;584(7821):430-436. doi: 10.1038/s41586-020-2521-4.
3. Jackson BR, Gold JAW, Natarajan P, Rossow J, Neblett Fanfair R, da Silva J, et al. Predictors at admission of mechanical ventilation and death in an observational cohort of adults hospitalized with COVID-19. *Clin Infect Dis*. 2021 Dec 6;73(11):e4141-e4151. doi: 10.1093/cid/ciaa1459.
4. Kim L, Garg S, O'Halloran A, Whitaker M, Pham H, Anderson EJ, et al. Risk Factors for Intensive Care Unit Admission and In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). *Clin Infect Dis*. 2020 May 4;72(9):e206-e214. doi: 10.1093/cid/ciaa1012.
5. Miller J, Fadel RA, Tang A, Perrotta G, Herc E, Soman S, et al. The Impact of Sociodemographic Factors, Comorbidities and Physiologic Response on 30-day Mortality in COVID-19 Patients in Metropolitan Detroit. *Clin Infect Dis*. 2021 Jun 1;72(11):e704-e710. doi: 10.1093/cid/ciaa1420.
6. Shah P, Owens J, Franklin J, Mehta A, Heymann W, Sewell W, et al. Demographics, comorbidities and outcomes in hospitalized Covid-19 patients in rural southwest Georgia. *Ann Med*. 2020;52(7):354-360. doi: 10.1080/07853890.2020.1791356.
7. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. *J Infect*. 2020;81(2):e16-e25. doi: 10.1016/j.jinf.2020.04.021.
8. Ioannou GN, Locke E, Green P, Berry K, O'Hare AM, Shah JA, et al. Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10□131 US Veterans With SARS-CoV-2 Infection. *JAMA Netw Open*. 2020;3(9):e2022310. doi: 10.1001/jamanetworkopen.2020.22310.
9. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black Patients and White Patients with Covid-19. *N Engl J Med*. 2020;382(26):2534-2543. 2020 Jun 25;382(26):2534-2543.
10. Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF, Fischer H, et al. Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization. *Ann Intern Med*. 2020. Nov 17;173(10):773-781. doi: 10.7326/M20-3742.
11. Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. *PLoS Med*. 2020;17(9):e1003321. doi: 10.1371/journal.pmed.1003321.
12. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. *Diabetes Metab Syndr*. 2020;14(4):535-545. doi: 10.1016/j.dsx.2020.04.044.
13. Kompaniyets L, Pennington AF, Goodman AB, Rosenblum HG, Belay B, Ko JY, et al. Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020-March 2021. *Prev Chronic Dis*. 2021;18:E66. doi: 10.5888/pcd18.210123.
14. Wang X, Jehi L, Ji X, Mazzone PJ. Phenotypes and Subphenotypes of Patients with COVID-19: a Latent Class Modeling Analysis. *Chest*. 2021. Jun;159(6):2191-2204. doi: 10.1016/j.chest.2021.01.057.

15. Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J, et al. COVID-19-Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(32):1074-1080. doi: 10.15585/mmwr.mm6932e2.
16. Wortham JM, Lee JT, Althomsons S, Latash J, Davidson A, Guerra K, et al. Characteristics of Persons Who Died with COVID-19 - United States, February 12-May 18, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(28):923-929. doi: 10.15585/mmwr.mm6928e1.
17. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. *JAMA Intern Med.* 2020;180(10):1345-1355. doi: 10.1001/jamainternmed.2020.3539.
18. Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. *BMC Infect Dis.* 2021;21(1):855. doi:10.1186/s12879-021-06536-3.
19. Olaya B, Moneta MV, Caballero FF, Tyrovolas S, Bayes I, Ayuso-Mateos JL, et al. Latent class analysis of multimorbidity patterns and associated outcomes in Spanish older adults: a prospective cohort study. *BMC Geriatr.* 2017;17(1):186. doi: 10.1186/s12877-017-0586-1.
20. Drew A, Linzer, Jeffrey B, Lewis (2011). poLCA: An R Package for Polytomous Variable Latent Class Analysis. *Journal of Statistical Software*, 42(10), 1-29. Available at: <http://www.jstatsoft.org/v42/i10/>. Accessed June 4, 2022.
21. R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: <https://www.R-project.org/>. Accessed June 4, 2022.
22. Noor FM, Islam MM. Prevalence and Associated Risk Factors of Mortality Among COVID-19 Patients: A Meta-Analysis. *J Community Health.* 2020 Dec;45(6):1270-1282.
23. Aggarwal G, Lippi G, Lavie CJ, Henry BM, Sanchis-Gomar F. Diabetes mellitus association with coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. *J Diabetes.* 2020;12(11):851-855. doi: 10.1111/1753-0407.13091.
24. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. *Intervirology.* 2020;1-12. doi: 10.1159/000512592.
25. Yehia BR, Winegar A, Fogel R, Fakihi M, Ottenbacher A, Jesser C, et al. Association of Race With Mortality Among Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) at 92 US Hospitals. *JAMA Netw Open.* 2020;3(8):e2018039. doi: 10.1159/000512592.
26. McCarty TR, Hathorn KE, Redd WD, Rodriguez NJ, Zhou JC, Bazarbashi AN, et al. How Do Presenting Symptoms and Outcomes Differ by Race/Ethnicity Among Hospitalized Patients with COVID-19 Infection? Experience in Massachusetts. *Clin Infect Dis.* 2021 Dec 6;73(11):e4131-e4138. doi: 10.1093/cid/ciaa1245.
27. Holtgrave DR, Barranco MA, Tesoriero JM, Blog DS, Rosenberg ES. Assessing racial and ethnic disparities using a COVID-19 outcomes continuum for New York State. *Ann Epidemiol.* 2020;48:9-14. doi: 10.1016/j.annepidem.2020.06.010.
28. Divo MJ, Martinez CH, Mannino DM. Ageing and the epidemiology of multimorbidity. *Eur Respir J.* 2014;44(4):1055-1068. doi: 10.1183/09031936.00059814.

29. Piccirillo JF, Vlahiotis A, Barrett LB, Flood KL, Spitznagel EL, Steyerberg EW. The changing prevalence of comorbidity across the age spectrum. *Crit Rev Oncol Hematol* 2008;67(2):124-132. doi: 10.1016/j.critrevonc.2008.01.013.
30. Daily Updates of Totals by Week and State: Provisional Death Counts for Coronavirus Disease 2019 (COVID-19), Available at: <https://www.cdc.gov/nchs/nvss/vsrr/covid19/index.htm>, Accessed March 22, 2021.
31. Turk MA, Landes SD, Formica MK, Goss KD. Intellectual and developmental disability and COVID-19 case-fatality trends: TriNetX analysis. *Disabil Health J*. 2020;13(3):100942. doi: 10.1016/j.dhjo.2020.100942.
32. Adams SH, Schaub JP, Nagata JM, Park MJ, Brindis CD, Irwin CE, Jr. Young Adult Perspectives on COVID-19 Vaccinations. *J Adolesc Health*. 2021;69(3):511-514. doi: 10.1016/j.jadohealth.2021.06.003.

Table 1: Demographic characteristics and latent class analysis of deaths with COVID-19, February 12–May 12, 2020.

		Latent Class Analysis Class						
		Diabetes/CVD (32%)		CVD without Diabetes (19%)		Minimal Prevalence (49%)		
Characteristic	Total (%) ^a	No. (%)	% by row	No. (%)	% by row	No. (%)	% by row	p-value
Total	12340 (100)	3955 (100)	32%	2387 (100)	19%	5998 (100)	49%	
Sex								
Male	7331 (60)	2389 (61)	33%	1396 (59)	19%	3546 (59)	48%	p=0.53
Female	4973 (40)	1553 (39)	31%	985 (41)	20%	2435 (41)	49%	
Age, yrs								
<45	511 (4)	127 (3)	25%	111 (5)	22%	273 (5)	53%	p<0.001
45-54	794 (6)	294 (7)	37%	150 (6)	19%	350 (6)	44%	
55-64	1748 (14)	780 (20)	45%	310 (13)	18%	658 (11)	38%	
65-74	2827 (23)	1063 (27)	38%	479 (20)	17%	1285 (21)	45%	
75-84	3332 (27)	1036 (26)	31%	653 (27)	20%	1643 (27)	49%	
≥85	3114 (25)	651 (16)	21%	681 (29)	22%	1782 (30)	57%	
Race/ethnicity								
White, non-Hispanic	3902 (32)	862 (22)	22%	943 (40)	24%	2097 (35)	54%	p<0.01
Black, non-Hispanic	2901 (24)	1276 (32)	44%	533 (22)	18%	1092 (18)	38%	
Asian, non-Hispanic	639 (5)	233 (6)	36%	81 (3)	13%	325 (5)	51%	
Other, non-Hispanic	655 (5)	236 (6)	36%	115 (5)	18%	304 (5)	46%	
Hispanic	2648 (21)	989 (25)	37%	410 (17)	15%	1249 (21)	47%	

Location of death								p<0.01
Home	282 (2)	75 (2)	27%	54 (2)	19%	153 (3)	54%	
Hospital	8093 (66)	2816 (71)	35%	1551 (65)	19%	3726 (62)	46%	
Emergency department	612 (5)	199 (5)	33%	101 (4)	17%	312 (5)	51%	
Hospice	51 (0)	12 (0)	24%	13 (1)	25%	26 (0)	51%	
Long-term care	868 (7)	133 (3)	15%	198 (8)	23%	537 (9)	62%	
Unknown	1446 (12)	310 (8)	21%	250 (10)	17%	886 (15)	61%	
Number of comorbidity groups								
0	3351 (27)	0 (0)	0%	0 (0)	0%	3351 (56)	100%	
1	2610 (21)	0 (0)	0%	0 (0)	0%	2610 (44)	100%	
2–3	4783 (39)	2629 (66)	55%	2117 (89)	44%	37 (1)	1%	
4–7	1596 (13)	1326 (34)	83%	270 (11)	17%	0 (0)	0%	
Comorbidity group								p<0.01
CVD	7148 (58)	3668 (93)		2128 (89)		1352 (23)		
Diabetes	4397 (36)	3955 (100)		0 (0)		442 (7)		
Renal disease	2430 (20)	1500 (38)		804 (34)		126 (2)		
Chronic lung disease	2263 (18)	1138 (29)		933 (39)		192 (3)		
Immunocompromised	1955 (16)	927 (23)		835 (35)		193 (3)		
Neurologic disease	1824 (15)	652 (16)		874 (37)		298 (5)		
Obesity	912 (7)	558 (14)		292 (12)		62 (1)		
Liver disease	363 (3)	178 (5)		166 (7)		19 (0)		

Abbreviations: CVD=cardiovascular disease.

Geographic locations included: Alaska, California, Colorado, Connecticut, Georgia, Hawaii, Indiana, Louisiana, Maine, Michigan, Minnesota, North Carolina, New Jersey, New York City, Oregon, Pennsylvania, Rhode Island, Tennessee, Utah, Vermont, Virginia, Washington, and Wisconsin. The total case count is 12,340; however sum of cases within each characteristic do not sum to this number due to exclusion of missing cases.

Comorbidities included CVD (congenital heart disease, coronary artery disease, congestive heart failure, hypertension, cerebrovascular accident/stroke, valvular heart disease, conduction disorders or dysrhythmias, pulmonary hypertension, dyslipidemia, thrombosis, other cardiovascular disease), diabetes mellitus types I and II, chronic lung disease (chronic obstructive pulmonary disease/emphysema, asthma, tuberculosis, other chronic lung diseases), immunosuppression (cancer, human immunodeficiency virus [HIV] infection, lupus, ulcerative colitis Crohn's disease, identified as being immunosuppressed), chronic kidney disease (chronic kidney disease, end-stage renal disease, other kidney diseases), neurologic conditions (dementia, seizure disorder, other neurologic conditions), chronic liver disease (cirrhosis, alcoholic hepatitis, chronic liver disease, end-stage liver disease, hepatitis B, hepatitis C, nonalcoholic steatohepatitis, other chronic liver diseases), and obesity (body mass index ≥ 30 kg/m²). Each comorbidity (e.g., stroke) was only coded in one category. A decedent with comorbidities in the same group (e.g., heart failure and stroke) was only counted in that comorbidity group (e.g., cardiovascular disease) once.

P-values for each variable tests whether the variable and the Latent Class Analysis classes are related.

^aUses 12,340 as denominator for percentage calculations.

Table 2: Latent class analysis by age and prevalence of comorbidity group among of deaths with COVID-19, February 12–May 12, 2020.

Age, yrs	Class	Class Description	No (%)	Prevalence of comorbidity group							
				CVD	Diabetes	Obesity	Renal Disease	Immuno	Chronic Lung	Neurologic	Liver Disease
<45	Class 1	CVD/Renal	26 (5)	100%	77%	12%	96%	65%	58%	54%	27%
	Class 2	CVD	215 (42)	85%	48%	49%	22%	19%	20%	13%	4%
	Class 3	Minimal Prevalence	270 (53)	0%	17%	8%	3%	9%	7%	9%	5%
45-54	Class 1	Immuno/Liver	57 (7)	46%	12%	33%	26%	65%	26%	46%	58%
	Class 2	CVD	368 (56)	92%	70%	31%	31%	23%	30%	11%	2%
	Class 3	Minimal Prevalence	369 (46)	14%	16%	7%	1%	5%	6%	4%	3%
55-64	Class 1	Immuno/CVD	211 (21)	92%	63%	25%	57%	100%	53%	18%	22%
	Class 2	CVD	760 (43)	95%	82%	29%	34%	8%	29%	16%	5%
	Class 3	Minimal Prevalence	777 (44)	26%	15%	3%	4%	10%	6%	10%	2%
65-74	Class 1	Diabetes/CVD	525 (19)	95%	100%	5%	29%	0%	0%	9%	0%
	Class 2	CVD	906 (32)	98%	57%	16%	43%	46%	54%	20%	11%

75-84	Class 3	Minimal Prevalence	1396 (49)	24%	10%	1%	4%	6%	5%	8%	1%
	Class 1	Renal/CVD	547 (16)	94%	81%	10%	96%	33%	38%	16%	6%
	Class 2	CVD	1508 (45)	94%	40%	2%	7%	18%	23%	21%	1%
≥85	Class 3	Minimal Prevalence	1277 (38)	0%	7%	0%	4%	5%	5%	5%	1%
	Class 1	CVD/Renal	326 (10)	98%	75%	8%	98%	33%	42%	20%	2%
	Class 2	CVD	1480 (48)	95%	28%	1%	12%	15%	19%	31%	1%
	Class 3	Minimal Prevalence	1308 (42)	0%	4%	0%	2%	2%	3%	8%	0%

Abbreviations: CVD=cardiovascular disease, Immuno=Immunocompromised.

Comorbidities included CVD (congenital heart disease, coronary artery disease, congestive heart failure, hypertension, cerebrovascular accident/stroke, valvular heart disease, conduction disorders or dysrhythmias, pulmonary hypertension, dyslipidemia, thrombosis, other cardiovascular disease), diabetes mellitus types I and II, chronic lung disease (chronic obstructive pulmonary disease/emphysema, asthma, tuberculosis, other chronic lung diseases), immunosuppression (cancer, human immunodeficiency virus [HIV] infection, lupus, ulcerative colitis, Crohn's disease, identified as being immunosuppressed), chronic kidney disease (chronic kidney disease, end-stage renal disease, other kidney diseases), neurologic conditions (dementia, seizure disorder, other neurologic conditions), chronic liver disease (cirrhosis, alcoholic hepatitis, chronic liver disease, end-stage liver disease, hepatitis B, hepatitis C, nonalcoholic steatohepatitis, other chronic liver diseases), and obesity (body mass index ≥ 30 kg/m²). Each comorbidity (e.g., stroke) was only coded in one category. A decedent with comorbidities in the same group (e.g., heart failure and stroke) was only counted in that comorbidity group (e.g., cardiovascular disease) once.